Welcome to our dedicated page for Repare Therapeutics SEC filings (Ticker: RPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Repare Therapeutics Inc. filings document the company's transition from a Nasdaq-listed clinical-stage precision oncology issuer to an acquired company with common shares removed from exchange listing and Exchange Act reporting obligations terminated or suspended. The record includes 8-K disclosures for shareholder voting on a Québec plan of arrangement, completion of the acquisition, material agreements, governance and compensation matters, clinical Regulation FD disclosure for the RP-1664 LIONS trial, and reported operating results.
Form 25 and Form 15 filings document the removal of Repare common shares from Nasdaq listing and the termination or suspension of Exchange Act registration and reporting duties. Earlier disclosures also identify the company's common-share capital structure, proxy matters, governance actions, and corporate-status reporting.
Repare Therapeutics Inc. — Blue Owl Capital Holdings LP filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 5 percent or less of the company's common shares. The statement references cover-page rows for the exact share and percentage figures and is signed by Karen Hager, Chief Compliance Officer.
Repare Therapeutics Inc. saw its largest shareholders cashed out in a merger. Investment funds affiliated with BVF Partners, including Biotechnology Value Fund, Biotechnology Value Fund II and Biotechnology Value Trading Fund OS, reported the disposition of their Repare common shares on January 28, 2026 in connection with a completed acquisition by XenoTherapeutics Inc. Under the arrangement, each common share was exchanged for $2.20 in cash plus one contingent value right for potential additional cash payments, and the BVF-related entities now report holding zero Repare shares after the transaction.
Repare Therapeutics Inc. has been acquired by XenoTherapeutics, Inc. through its subsidiary Xeno Acquisition Corp. Effective January 28, 2026, the buyer acquired all outstanding common shares.
Shareholders received $2.20 in cash per share plus one contingent value right per share for potential future cash payments. Following this transaction, the BVF funds and related reporting persons now report owning 0 shares, representing 0% of Repare’s outstanding common shares and have ceased to be beneficial owners of more than 5% of the company.
Repare Therapeutics director Carol Schafer has exited her position in the company through a cash-and-rights buyout. On January 28, 2026, she disposed of 8,000 common shares and had 37,941 stock options cancelled under an Arrangement Agreement involving XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation.
Each common share was exchanged for $2.20 in cash plus one contingent value right (CVR). Each option was cancelled in return for $2.20 minus its exercise price per underlying share, plus one CVR per underlying share, effectively cashing out her remaining equity in connection with the acquisition of all Repare common shares.
Repare Therapeutics director Ann D. Rhoads reported the disposition of 4,000 common shares in connection with the company’s acquisition. On January 28, 2026, all of her shares were exchanged under an Arrangement Agreement with XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation.
Each Repare share was converted into $2.20 in cash plus one non‑transferable contingent value right (CVR), and Rhoads now reports owning zero Repare common shares following the transaction.
Repare Therapeutics Inc. director Civik Thomas reported the disposition of 7,500 common shares on January 28, 2026, reducing his reported holdings to zero. The Form 4 lists the transaction code as "D" for a non-derivative disposition.
According to the Arrangement Agreement dated November 14, 2025 among Repare Therapeutics, XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation, each Repare common share was acquired by the purchaser in exchange for $2.20 in cash per share plus one non-transferable contingent value right (CVR) per share.
Repare Therapeutics EVP and CFO Steve Forte reported the cancellation of his equity holdings following the company’s acquisition. On January 28, 2026, 56,786 common shares were disposed of, including shares from restricted stock units and the employee stock purchase plan, as part of an Arrangement Agreement.
Under this agreement, all issued and outstanding Repare common shares were acquired for $2.20 in cash per share plus one contingent value right (CVR). Several employee stock options to buy common shares, with various exercise prices and expirations, were also cancelled in exchange for $2.20 minus the option exercise price per underlying share plus one CVR per underlying share.
Repare Therapeutics SVP, Finance and CAO, Sandra Isabelle Barros Alves reported the cancellation of 31,622 common shares and two employee stock option grants on January 28, 2026 in connection with an Arrangement Agreement with XenoTherapeutics.
The common shares, including 18,800 underlying restricted stock units, and the options were exchanged for $2.20 in cash per share plus one non-transferable contingent value right (CVR) per share, with options receiving $2.20 less the applicable exercise price plus one CVR per underlying share. After these transactions, she reported holding zero common shares and zero derivative securities.
Pursuant to the Arrangement Agreement, Xeno Acquisition Corp. acquired all issued and outstanding Repare common shares on the same cash-and-CVR terms.